Jean Noël B.
- Country
- France
- Department
- Hématologie Clinique
Research Overview
- Phase II Study of Quadruplet Induction and Consolidation with Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High-Risk Multiple Myeloma
- Phase 3 Study of Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid in Acute Myeloid Leukemia Patients Aged 18-60
- Evaluation of CAEL-101 and Plasma Cell Dyscrasia Treatment Efficacy and Safety in Treatment-Naïve Mayo Stage IIIa AL Amyloidosis Patients
Data & Insights
Has run more than one trial at 111 of 218 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of newly diagnosed multiple myeloma, with particular emphasis on innovative therapeutic approaches in post-transplant care.
- Multiple Myeloma Treatment
- Stem Cell Transplantation
- Maintenance Therapy
Research interests center on evaluating novel therapeutic agents for maintenance treatment following autologous stem cell transplantation in multiple myeloma patients.
Therapeutic Innovation
The investigator focuses on developing and assessing novel maintenance therapies for blood cancer patients, with particular attention to treatment response optimization.
- Response Assessment
- Dose Level Evaluation
- Treatment Efficacy
Special interest in measuring therapeutic responses ranging from partial response to stringent complete response in multiple myeloma patients.
Transplant Medicine
The investigator's expertise encompasses autologous stem cell transplantation procedures and subsequent therapeutic strategies in hematologic malignancies.
- Post-Transplant Care
- Treatment Optimization
- Long-term Outcomes
Focus areas include improving post-transplant outcomes through targeted maintenance strategies in newly diagnosed patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.